Arca Biopharma | ABIO - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
Alterity Therapeutics Limited AUD 8.67M 893.38K 2025-12
Amgen USD 5.69B 6B 2026-09
Arca Biopharma USD 36.43M 2M 2026-03
Biogen USD 2.32B 663.6M 2026-09
Brainstorm Cell Therapeutics USD 2.05M 198K 2026-03
Bristol-Myers Squibb USD 23.4B 1.08B 2026-09
Capricor Therapeutics USD 29.16M 2.87M 2025-12
Cipla INR 63.61B 1.3B 2026-09
Clal Biotechnology ILS 5.15M 9.47M 2022-12
Compugen USD 11.44M 246K 2026-06
CSL USD 5.7B 2.82B 2025-12
Cytokinetics USD 214.64M 6.85M 2026-09
Daiichi Sankyo JPY 483.8B 5.85B 2026-09
Gilead Sciences USD 13.04B 9.09B 2026-09
GlaxoSmithKline GBP 6.03B 227M 2026-09
Grifols EUR 1.99B 217.4M 2025-12
Laboratory Of America USD 3.39B 117.6M 2026-09
Myriad Genetics USD 212.8M 16.2M 2025-12
Otsuka Holdings JPY 567.81B 6.18B 2026-09
Pfizer USD 89B 3.81B 2026-09
United Therapeutics USD 6.28B 124.3M 2026-09